On March 6, 2023 Biotroy Therapeutics reported the successful completion of a second round of financing (Press release, Biotroy Therapeutics, MAR 6, 2023, View Source [SID1234655090]). This round of financing is jointly funded by Co-win Ventures (leading investor), HUNTBEST Capital, Sangel Capital, and Shanghai Biomedical Fund (the original investor).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Founded in 2019, BioTroy Therapeutics is a biopharmaceutical company dedicated to the research and development of first-in-class therapies for the treatment of cancer and immunological disorders.

Dr Jie Xu, as the founder of the company, is a senior researcher in the fields of translational oncology and immunotherapy.

The main pipelines of BioTroy aim at tumors that are refractory to PD-1/PD-L1 inhibitor therapy. Major studies related to IND application have been completed and encouraging results have been obtained.

With this new investment, BioTroy will further accelerate its development in tumor immune product pipelines of new target.